Resources
Get helpful information about MRD and M-inSight®
All
Articles
Documentation
Events
Posters
Publications
Clonotypic Peptide Mass Spectrometry to Define Functional Cure in Patients with Multiple Myeloma Undergoing Maintenance Cessation - ASH 2024
MRD tracking in blood using a de novo sequencing from SPEP gel of M-protein in Multiple Myeloma Patients - IMS 2024
Single MS assay targeting m-protein, therapeutic antibodies, polyclonal immunoglobulins provides unique insight into therapy response kinetics in patients with MM - EMN 2024
Monitoring of Systemic Light-Chain Amyloidosis patients using Mass Spectrometry (M-inSight) in serum - ASH 2023
Multiple Myeloma MRD tracking in blood using ultra sensitive Mass Spectrometry (M-inSight) - ASH 2023
Personalized mass spectrometry as a tool for minimal residual disease detection in the blood of myeloma patients - IMS 2023
Development of a Targeted MS Serum Assay To Quantify M‑Protein in the Presence of Therapeutic Monoclonal Antibodies - J Proteome Res. 2018
- 01
- 02
